drugset / Trial / NCT04165993
Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, three-cohort phase 2 study of KN026 in subjects with advanced breast Cancer.
Timeline
- Start
- 2019-12-31
- Primary completion
- 2021-05-27
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ERFONRILIMAB | Monoclonal antibody | 5 mg/kg | — |
| Subject | KN026 | Monoclonal antibody | 30 mg/kg | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |